This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA)

Tipranks - Tipranks - Wed May 13, 7:56AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mettler-Toledo (MTD) and Neumora Therapeutics, Inc. (NMRA).

Claim 55% Off TipRanks

Mettler-Toledo (MTD)

In a report released today, Kallum Titchmarsh from Morgan Stanley maintained a Hold rating on Mettler-Toledo, with a price target of $1275.00. The company’s shares closed last Monday at $1078.53.

According to TipRanks.com, Titchmarsh is a 1-star analyst with an average return of -0.8% and a 34.3% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Mettler-Toledo has an analyst consensus of Moderate Buy, with a price target consensus of $1374.25, which is a 23.1% upside from current levels. In a report released today, TipRanks – PerPlexity also downgraded the stock to Hold with a $1209.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Neumora Therapeutics, Inc. (NMRA)

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $6.00. The company’s shares closed last Monday at $1.87, close to its 52-week low of $1.02.

According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of 17.5% and a 45.5% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amylyx Pharmaceuticals Inc, and EyePoint Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neumora Therapeutics, Inc. with a $9.33 average price target, representing a 404.3% upside. In a report issued on May 7, Needham also maintained a Buy rating on the stock with a $8.00 price target.

Read More on MTD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).